Publications by authors named "Rhys D Jones"

Claim this Profile
T
Translational PK/PD: a retrospective analysis of performance and impact from a drug portfolio.
Rasmus Jansson-Löfmark, Markus Fridén, Lassina Badolo, Christine Ahlström, Ian Gurrell, Rhys DO Jones

Drug Discov Today· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.
Erica Banks, Michael Grondine, Deepa Bhavsar, Evan Barry, Jason G Kettle, Rhys DO Jones

Sci Transl Med· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.
Alwin G Schuller, Evan R Barry, Rhys D O Jones, Ryan E Henry, Melanie M Frigault

Clin Cancer Res· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo.
Sarah A Loddick, Sarah J Ross, Andrew G Thomason, David M Robinson, Graeme E Walker, Rhys D O Jones

Mol Cancer Ther· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-based drug discovery: implementation and impact.
Sandra A G Visser, Malin Aurell, Rhys D O Jones, Virna J A Schuck, Ann-Charlotte Egnell

Drug Discov Today· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.
Robert H Bradbury, David G Acton, Nicola L Broadbent, A Nigel Brooks, Gregory R Carr, Rhys D O Jones

Bioorg Med Chem Lett· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution.
Rhys Do Jones, Hannah M Jones, Malcolm Rowland, Christopher R Gibson, James W T Yates

J Pharm Sci· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.
Ragini Vuppugalla, Punit Marathe, Handan He, Rhys D O Jones, James W T Yates, Hannah M Jones

J Pharm Sci· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets.
Patrick Poulin, Hannah M Jones, Rhys Do Jones, James W T Yates, Christopher R Gibson

J Pharm Sci· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
Patrick Poulin, Rhys D O Jones, Hannah M Jones, Christopher R Gibson, Malcolm Rowland

J Pharm Sci· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.
Barbara J Ring, Jenny Y Chien, Kimberly K Adkison, Hannah M Jones, Malcolm Rowland, Rhys Do Jones

J Pharm Sci· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of indole-derived long acting beta2-adrenoceptor agonists for the treatment of asthma and COPD.
Alan D Brown, Mark E Bunnage, Paul A Glossop, Mark Holbrook, Rhys D Jones

Bioorg Med Chem Lett· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel one pot synthesis of silver nanoparticle-polymer composites by supercritical CO2 polymerisation in the presence of a RAFT agent.
Tom Hasell, Kristofer J Thurecht, Rhys D W Jones, Paul D Brown, Steven M Howdle

Chem Commun (Camb)· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis